One next step will be to clone the TCRs from the expanded TFK clones and determine their antigen specificity, i.e. whether they are engaged by lymphoma-derived peptides or whether CXCR5+ TFK cells, which naturally home to the atypical follicles, should be equipped with a lymphoma-recognizing CAR. This evidence concerns the gene CXCR5 and lymphoma.